Axplora Group announces €50m expansion of GLP-1 manufacturing site

The expansion in France will position Mourenx as a centre of excellence in the Axplora network for contract manufacturing of APIs and drug substances for FDA-approved biologics,.

By upgrading Mourenx’s infrastructure and capabilities, Axplora and its subsity Novasep SA will solidify its position in peptide purification in a biologics environment and support the development of next-generation therapies, including GLP-1 drugs to treat diabetes and obesity. Sales of obesity medicines alone are forecasted to reach US$173.5 bn in the seven major biopharma markets by 2031, according to a new report published by GlobalData yesterday, a leading data and analytics company.

“We target having the facility BLA-ready in 15 months,” stated Dr. Pere Patón-Morales, Chief Operating Officer at Axplora Group. According to the CDMO, construction and infrastructure development will begin immediately, with first supplies of GLP-1 therapies expected in 2026.

Axplora has been a trusted CDMO partner for over 900 of the world’s leading pharmaceutical and biotech companies, formed from the integration of API specialists PharmaZell, Farmabios, and ADC payload and conjugation CDMO Novasep.